KR101150504B1 - 이리노테칸 염산염의 신규의 결정형 - Google Patents

이리노테칸 염산염의 신규의 결정형 Download PDF

Info

Publication number
KR101150504B1
KR101150504B1 KR1020087009534A KR20087009534A KR101150504B1 KR 101150504 B1 KR101150504 B1 KR 101150504B1 KR 1020087009534 A KR1020087009534 A KR 1020087009534A KR 20087009534 A KR20087009534 A KR 20087009534A KR 101150504 B1 KR101150504 B1 KR 101150504B1
Authority
KR
South Korea
Prior art keywords
irinotecan hydrochloride
crystalline form
irinotecan
hydrochloric acid
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087009534A
Other languages
English (en)
Korean (ko)
Other versions
KR20080059244A (ko
Inventor
슈-핑 천
핀-지에 하른
Original Assignee
시노팜 싱가포르 피티이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시노팜 싱가포르 피티이 리미티드 filed Critical 시노팜 싱가포르 피티이 리미티드
Publication of KR20080059244A publication Critical patent/KR20080059244A/ko
Application granted granted Critical
Publication of KR101150504B1 publication Critical patent/KR101150504B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020087009534A 2005-09-20 2006-09-19 이리노테칸 염산염의 신규의 결정형 Expired - Fee Related KR101150504B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71882705P 2005-09-20 2005-09-20
US60/718,827 2005-09-20
PCT/US2006/036437 WO2007035709A2 (en) 2005-09-20 2006-09-19 Novel crystal forms of irinotecan hydrochloride

Publications (2)

Publication Number Publication Date
KR20080059244A KR20080059244A (ko) 2008-06-26
KR101150504B1 true KR101150504B1 (ko) 2012-07-09

Family

ID=37889452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087009534A Expired - Fee Related KR101150504B1 (ko) 2005-09-20 2006-09-19 이리노테칸 염산염의 신규의 결정형

Country Status (14)

Country Link
US (1) US7435818B2 (enExample)
EP (2) EP2082741A1 (enExample)
JP (1) JP5119153B2 (enExample)
KR (1) KR101150504B1 (enExample)
CN (1) CN101277694B (enExample)
AR (1) AR056082A1 (enExample)
AT (1) ATE460162T1 (enExample)
AU (1) AU2006292328B2 (enExample)
BR (1) BRPI0616308A2 (enExample)
CA (1) CA2623117C (enExample)
DE (1) DE602006012871D1 (enExample)
ES (1) ES2343204T3 (enExample)
NZ (1) NZ566807A (enExample)
WO (1) WO2007035709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101318964B (zh) * 2007-06-07 2010-12-15 上海迪赛诺医药发展有限公司 盐酸伊立替康新晶型及其制备方法
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
IT1391757B1 (it) * 2008-11-11 2012-01-27 Antibioticos Spa Irinotecan cloridrato cristallino e metodi per la sua preparazione
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012007952A1 (en) * 2010-07-12 2012-01-19 Hetero Research Foundation Novel polymorph of irinotecan hydrochloride
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
CN102850363B (zh) * 2012-09-18 2013-07-10 山东罗欣药业股份有限公司 盐酸伊立替康化合物及其药物组合物
EP2986739B1 (en) 2013-04-15 2018-04-04 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy
CN105713004A (zh) * 2016-03-23 2016-06-29 杭州华东医药集团新药研究院有限公司 一种高品质盐酸伊立替康三水合物晶型的制备方法
US10919905B2 (en) * 2019-05-16 2021-02-16 Scinopharm Taiwan, Ltd. Polymorphism for irinotecan free base

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191614A1 (en) 2000-01-07 2005-09-01 Millenium Pharmaceuticals, Inc. High-throughput formation, identification and analysis of diverse solid forms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
MA24682A1 (fr) * 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
PL372318A1 (en) 2002-03-01 2005-07-11 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
CZ20022250A3 (cs) * 2002-06-27 2004-02-18 Pliva-Lachema A. S. Způsob výroby irinotekanu
AU2004215560B2 (en) 2003-02-25 2009-09-24 Kabushiki Kaisha Yakult Honsha Method for preparing polymorphism of irinotecan hydrochloride
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
ATE446299T1 (de) * 2005-02-07 2009-11-15 Fermion Oy Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
EP1928883B1 (en) * 2005-02-08 2013-10-30 Fermion Oy Process for the preparation of irinotecan hydrochloride

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191614A1 (en) 2000-01-07 2005-09-01 Millenium Pharmaceuticals, Inc. High-throughput formation, identification and analysis of diverse solid forms

Also Published As

Publication number Publication date
AU2006292328A1 (en) 2007-03-29
CA2623117A1 (en) 2007-03-29
US20070072890A1 (en) 2007-03-29
ES2343204T3 (es) 2010-07-26
KR20080059244A (ko) 2008-06-26
DE602006012871D1 (de) 2010-04-22
WO2007035709A3 (en) 2007-10-25
CA2623117C (en) 2013-12-10
EP1951235A4 (en) 2008-10-29
CN101277694B (zh) 2011-04-20
BRPI0616308A2 (pt) 2011-06-14
NZ566807A (en) 2011-05-27
WO2007035709A2 (en) 2007-03-29
JP2009508874A (ja) 2009-03-05
AR056082A1 (es) 2007-09-19
CN101277694A (zh) 2008-10-01
EP1951235A2 (en) 2008-08-06
EP2082741A1 (en) 2009-07-29
US7435818B2 (en) 2008-10-14
JP5119153B2 (ja) 2013-01-16
EP1951235B1 (en) 2010-03-10
ATE460162T1 (de) 2010-03-15
AU2006292328B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
KR100668400B1 (ko) 테트라히드로피리도에테르
EP3438099A1 (en) Vortioxetine pamoic acid salt and crystal form thereof
KR20080044841A (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
JPH02292281A (ja) ３―ｎ置換カルバモイル―インドール誘導体
WO1997030999A1 (en) Quinolones and their therapeutic use
BRPI0509595B1 (pt) Processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir
KR20040091083A (ko) 이리노테칸 히드로클로라이드의 결정성 다형체
JP5119153B2 (ja) イリノテカン塩酸塩の新規結晶形
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
AU2021381638A9 (en) Salt of benzothiazole compound, and crystal form and use thereof
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JP4566128B2 (ja) イリノテカン塩酸塩の結晶多形の製造方法
CN102993213A (zh) 有机化合物
US6576647B2 (en) Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
CN118344294A (zh) 一种具有镇痛活性的草乌甲素衍生物及其制备方法和应用
KR20080068052A (ko) 신규의 결정형
EP1259507B1 (en) Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one hydrochloride
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
RU2162695C1 (ru) Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
CN116283957A (zh) 唑吡坦水合物及其制备方法
CN110862386A (zh) 一种达沙替尼晶型及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20150416

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160419

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170420

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180417

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190417

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200522

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200522